Monday, August 02, 2010 11:42:03 AM
Here are some of the facts I know are true:
Paid pump last week - plain and simple
Look at when the posts came in last week. Many while we were sleeping. Double posts and pie in the sky posts talking about 12 cents this and 15 cents that when trading at roughly 5 cents.
Great quick money to be made by the flippers.
Buying shares like crazy leading up to the so called bellweather PR that was expected.
Volume unheard of on this stock.
Then the news hit. It was mundane and informational at best and the daytraders fled like crazy and this stock settled back in to the range it was trading prior to the frenzy. (actually a little higher, thanks to the flippers from me)
There is your increase in volume. The shares of NDYN traded up over 2 days and down in 1. Almost a complete wash of shares.
All the clowns left the carnival car.
The only clowns left are the few with the keys to the car. The ones at the carnival that get paid the most!
Remember, we were never here for the daytrade play to begin with and will be here for a long time until this stock rises to the level we each see fit as an exit point for ourselves once we evaluate risk versus reward.
From an extremely good source -
The company sold NO shares last week.
Shares in the float are still less than 6 million shares.
The company has not changed, still has huge contracts in place and more contracts to come for the remainder of 2010.
This stock will see a much higher price OVER TIME.
This could be over the next month but definetely over the next 3 to 6 months.
Projection - $.25 to $.50 cents fairly easily
So, if you want a daytrade go somewhere else. For others, if you believe in what you bought originally look at anything in the 5 cent range as a gift and a great buying opportunity as you should see a minimum gain of 500% by the latest January 31. Could see up to a 1,000% gain by October 31. Anything in between theses timeframes and price ranges I am pretty happy with.
GLTA and hope this helps.
All my info came from a credible source that I cannot divulge or the spiggot will be turned off!
Last post of the day as I am going Fishing!
Recent COEP News
- Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy • PR Newswire (US) • 10/15/2024 12:07:00 PM
- Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • PR Newswire (US) • 09/19/2024 11:07:00 AM
- Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders • PR Newswire (US) • 09/05/2024 12:07:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/16/2024 08:02:33 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/16/2024 08:01:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 09:26:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:25:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 09:00:33 PM
- Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering • PR Newswire (US) • 06/20/2024 12:47:00 PM
- Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting • PR Newswire (US) • 05/30/2024 12:47:00 PM
- Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 • PR Newswire (US) • 05/08/2024 12:47:00 PM
- Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting • PR Newswire (US) • 05/02/2024 12:47:00 PM
- Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award • PR Newswire (US) • 04/02/2024 12:47:00 PM
- Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK • PR Newswire (US) • 02/26/2024 02:00:00 PM
- Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections • PR Newswire (US) • 02/07/2024 12:30:00 PM
- Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 • PR Newswire (US) • 01/04/2024 12:30:00 PM
- Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 • PR Newswire (US) • 10/31/2023 01:01:00 PM
- Coeptis Therapeutics Announces $2 Million Private Placement • PR Newswire (US) • 10/24/2023 12:30:00 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM